AEON Biopharma, Inc. Market Cap ($9.05 Million)
Market Cap & Net Worth: AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. market cap. AEON Biopharma, Inc. (NYSE MKT:AEON) has a market capitalization of $9.05 Million ($9.05 Million) as of November 1, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #27208 globally and #5653 in its home market, demonstrating a -3.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AEON Biopharma, Inc.'s stock price $0.78 by its total outstanding shares 11643786 (11.64 Million). Also see AEON cash flow conversion for how efficiently the company converts equity into cash flow.
AEON Biopharma, Inc. Market Cap History (2021–2026)
AEON Biopharma, Inc. market cap history from 2021 to 2026. Data shows change from $113.06 Million to $9.05 Million (-38.91% CAGR). Check AEON Biopharma, Inc. stock price for real-time trading data and today's change.
AEON Biopharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AEON Biopharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AEON Biopharma, Inc. net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AEON by Market Capitalization
Companies near AEON Biopharma, Inc. in the global market cap rankings as of November 1, 2026. Also see balance sheet size of AEON Biopharma, Inc. for a full breakdown of the balance sheet.
Key companies related to AEON Biopharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of AEON Biopharma, Inc. (2021–2026)
Market capitalization of AEON Biopharma, Inc. from 2021 to today. Between 2021 and today, AEON Biopharma, Inc.'s market cap moved from $113.06 Million to $ 9.05 Million, with a yearly change of -38.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.05 Million | -29.36% |
| 2025 | $12.81 Million | +103.70% |
| 2024 | $6.29 Million | -92.50% |
| 2023 | $83.84 Million | -28.36% |
| 2022 | $117.02 Million | +3.50% |
| 2021 | $113.06 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of AEON Biopharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.05 Million USD |
| MoneyControl | $9.05 Million USD |
| MarketWatch | $9.05 Million USD |
| marketcap.company | $9.05 Million USD |
| Reuters | $9.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more